Side Effects Soar for Newer Classes of Diabetes Drugs !

A list of the newer classes of Type 2 diabetes drugs reads like alphabet soup: GLP-1, DPP-4, SLGT2.

But the list of possible side effects carries a much more somber tone: pancreatitis, pancreatic cancer, urinary infections, thyroid cancer, gastrointestinal issues, and renal and gallbladder problems.

In a groundbreaking report, AdverseEvents (AE), a California-based company that analyzes post-market side effect data, reveals the real-world problems with these newer drugs.

“The only way to fully review a drug’s safety is to track and monitor side effects as the general population begins utilizing the drugs on an ongoing basis, in real-world circumstances,” Brian Overstreet, CEO of AdverseEvents, said in a statement.

While it’s hard to argue with the data – real people reporting real side effects to the U.S. Food and Drug Administration (FDA) – the report is sure to face scrutiny. The primary point of controversy? Whether these drugs are or are not linked to pancreatic cancer.

The report says yes.

More on this story here.

Professor Emeritus Sir Frederic B Scuttle, Chief Research Scientist at The Broadmore Institute for Dietetic Research, stated yesterday, "we have spent over a gazillion Dollars trying to prove a meat and four low starch vegetable meal is dangerous, and so far drawn a blank, more research is required before we can give whole fresh food the all clear, for the safe control of type two diabetes"

Eddie